Drug Trial Radar · NCT05248646
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
Last checked: Nov 20, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
530
Actual
Start
Mar 15, 2022
Primary completion
May 13, 2026
Study completion Jan 19, 2027
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- Feb 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Primary Immunoglobulin A Nephropathy
Conditions
- Immunoglobulin A Nephropathy
Interventions
Sibeprenlimab 400 mgDrug
Solution for Injection
PlaceboDrug
Placebo s.c. q 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Urinary protein to creatinine ratio (uPCR) in a 24-hour collectionTime frame: At 9 months
Locations
308 sites in 31 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham - Site #336
Birmingham, Alabama
Mayo Clinic Arizona - Site #363
Phoenix, Arizona
University of Arkansas for Medical Sciences - Site #353
Little Rock, Arkansas
Amicis Research Center - Site #341
Granada Hills, California
University of CA San Diego - Site #351
La Jolla, California
California Institute of Renal Research - Site #371
La Mesa, California
Loma Linda University Health Care Clinical Trial Center Clinic - Site #372
Loma Linda, California
Academic Medical Research Institute - Site #333
Los Angeles, California
Kaiser Permanente - Southern California Permanente Medical Group SCPMG - LAMC - Site #325
Los Angeles, California
Stanford University - Site #370
Palo Alto, California
North America Research Institute - Site #335
San Dimas, California
University of California, San Francisco - Site #377
San Francisco, California
Colorado Kidney Care PC - Site #330
Denver, Colorado
Mayo Clinic in Florida - Site #321
Jacksonville, Florida
South Florida Research Institute - Site #323
Lauderdale Lakes, Florida
Columbus Research Group - Site #376
South Miami, Florida
Fides Clinical Research North Atlanta Kidney Specialists - Site #373
Atlanta, Georgia
Georgia Nephrology - Site #356
Lawrenceville, Georgia
University of Iowa Hospitals & Clinics - Site #359
Iowa City, Iowa
Kansas Nephrology Associates - Site #322
Wichita, Kansas
Ochsner Medical Center - Site #334
New Orleans, Louisiana
University of Maryland - Site #355
Baltimore, Maryland
MGH Harvard - Site #369
Boston, Massachusetts
Brigham and Women's Hospital, Division of Renal Medicine - Site #379
Boston, Massachusetts
Tufts Medical Center - Site #349
Boston, Massachusetts
Beth Israel Deaconess Medical Center - Site #337
Boston, Massachusetts
MGH Harvard - Site #369
Boston, Massachusetts
Brigham and Women's Hospital, Division of Renal Medicine - Site #379
Boston, Massachusetts
Tufts Medical Center - Site #349
Boston, Massachusetts
Beth Israel Deaconess Medical Center - Site #337
Boston, Massachusetts
UMASS Memorial Medical Center - Site #331
Worcester, Massachusetts
UMASS Memorial Medical Center - Site #331
Worcester, Massachusetts
St. Clair Nephrology Research - Site #320
Roseville, Michigan
University of Minnesota - Site #345
Minneapolis, Minnesota
Mayo Clinic - Rochester - Site #332
Rochester, Minnesota
University of Nebraska Medical Center - Site #347
Omaha, Nebraska
Davita Clinical Research - Las Vegas - Site #327
Las Vegas, Nevada
Northwell Health - North Shore University Hospital NSUH - Site #346
Great Neck, New York
New York University Grossman School of Medicine - Site #362
New York, New York
Jacobi Medical Center - Site #364
The Bronx, New York
Showing 40 of 308 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.